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Abstract
The present study was designed to demonstrate the potential of an optimized histology directed 
protein identification combined with imaging mass spectrometry technology to reveal and identify 
molecules associated to ectopic calcification in human tissue. As a proof of concept, mineralized 
and non-mineralized areas were compared within the same dermal tissue obtained from a patient 
affected by Pseudoxanthoma elasticum, a genetic disorder characterized by calcification only at 
specific sites of soft connective tissues. Data have been technically validated on a contralateral 
dermal tissue from the same subject and compared with those from control healthy skin. Results 
demonstrate that this approach 1) significantly reduces the effects generated by techniques that, 
disrupting tissue organization, blend data from affected and unaffected areas; 2) demonstrates that, 
abolishing differences due to inter-individual variability, mineralized and non-mineralized areas 
within the same sample have a specific protein profile and have a different distribution of 
molecules; 3) avoiding the bias of focusing on already known molecules, reveals a number of 
proteins that have been never related to the disease nor to the calcification process, thus paving the 
way for the selection of new molecules to be validated as pathogenic or as potential 
pharmacological targets.
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1. Introduction
Calcium and phosphate deposition in soft connective tissues occurs in a number of genetic 
diseases, in metabolic disorders, such as uremia, hyperparathyroidism and diabetes, or 
secondary to inflammation or atherosclerosis. Numerous proteins have been identified to be 
involved in bone calcification as well as in ectopic mineralization, suggesting that an active 
and dynamic balance of pro-calcifying and anti-calcifying mechanisms take place in both 
physiological and pathological calcification [1]. Nevertheless it is still unclear whether 
calcification affects particular matrix components in specific organs/tissues, whereas other 
areas remain unaffected and which molecules/pathways could be targeted for 
pharmacological approaches. To address these questions, investigations performed so far 
have looked at the specific expression/localization of already known proteins [2] or have 
used cell lines and tissue extracts to pick up unknown gene/proteins by means of “omic” 
techniques [3-5]. However, the major difficulty of these techniques is the ability to analyse a 
large number of proteins without losing the morphology and the tissue architecture and, 
even more importantly, to discriminate which proteins belong to normal or to pathologic 
areas. Therefore, in this study, on-tissue analyses were carried out by Matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI MS) (profiling and imaging) [6-7] as a 
consolidated tool for the analysis of biological and clinical tissue samples [8-12]. This 
approach has several advantages: i) endogenous (locally synthesised by cells) as well as 
exogenous (derived from the blood stream) molecules can be analysed directly from the 
tissue in their native environment, without homogenization, thus preserving spatial 
relationship of molecules within a specimen; ii) it does not require the use of antibodies; iii) 
it can map the expression of hundreds of proteins from a single (8 μm thick) tissue section.
However, MALDI MS, although leading to the detection of a large number of peptides and 
small proteins (up to 25 kDa), cannot be currently utilized for larger proteins (exceeding 25 
kDa). In order to detect also proteins larger than 25 kDa, we have applied a histology-
directed mass spectrometry protein identification [13] using hydrogel discs as carriers for 
the enzyme, thus allowing the digestion to take place directly on discrete tissue areas 
preserving the relationship between molecular information and tissue architecture.
As the technology advances, the application of MALDI MS as well as of miniaturized 
hydrogel devices for histology directed on-tissue protein digestion in the clinic will continue 
to expand, enabling to play a central role in the diagnosis and prognosis of diseases and in 
the evaluation of patient's therapy.
Therefore, we have combined this MS-based technology in order to investigate skin biopsies 
from a patient affected by Pseudoxanthoma elasticum, a rare genetic disorder characterized 
by a progressive calcification occurring in specific areas of soft connective tissues, whereas 
other regions remain unaffected [14]. Proteomic analyses were performed on mineralized 
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and non-mineralized areas of the same biopsy, and data compared with those from a control 
healthy tissue.
2. Material and Methods
2.1 Tissue specimen collection
Patient was a woman 46 years old affected by Pseudoxanthoma elasticum (PXE). The 
disease was clinically diagnosed at the age of 15 years by the presence of typical dermal 
alterations (Fig. 1a) and by ocular angioid streaks. Biomolecular analyses confirmed the 
clinical diagnosis of PXE revealing two causative missense mutations in the ABCC6 gene: 
one on exon 12 (c.1553G>A, p.Arg518Gln) and the other on exon 24 (c.3389C>T, 
p.Thr1130Met).
Control tissue was obtained from a woman 47 years old undergoing elective cosmetic 
surgical procedures. No connective tissue alterations were present, nor any clinically 
relevant condition.
Consent was obtained to use these specimens for research purposes in accordance with the 
Declaration of Helsinki protocol.
After surgery, skin samples were immediately placed in fixatives for morphological analyses 
or frozen in liquid nitrogen and stored at -80°C until ready for processing and preparation 
for mass spectrometry analysis.
2.2 Light and electron microscopy
For the demonstration of calcified elastic fibres, skin specimens (approximately 1cm3) were 
routinely fixed in 10% (v/v) formalin in water, dehydrated and embedded in paraffin. Five to 
seven micron thick sections were collected on glass slides and processed for the von Kossa 
stain. Briefly, sections were deparaffinized and hydrated, stained for approximately hour 
with 5% (w/v) silver nitrate in water under a UV-lamp, rinsed with water, immersed for 5 
minutes in 5% (w/v) thiosulfate in water and finally observed with a Zeiss Axiophot light 
Microscope (Jena, Germany).
For ultrastructural observations, specimens were cut in 1mm3 fragments and routinely fixed 
in 2.5% (v/v) glutaraldehyde (Agar Scientific, Stansted, UK) in Tyrode's buffer pH 7.2 (135 
mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 12 mM NaHCO3, 0.4 mM NaH2PO4, 
5.5 mM Glucose), postfixed in 1% (v/v) osmium tetroxide (Agar Scientific) in Tyrode's 
buffer, dehydrated and embedded in Spurr resin (Agar Scientific). Ultrathin sections 
(approximately 70-80nm) were stained with uranyl acetate and lead citrate and observed 
with a TEM Jeol 2010 (Jeol, Tokyo, Japan)
2.3 MS-based techniques: the strategy
A workflow of the analytical approach and technologies we have combined in this study is 
presented in Fig. 2.
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A typical experimental design for MALDI MS protein analysis is made of 3 steps: sample 
preparation, data acquisition (profiling and imaging) and data processing.
In the profiling experiment, the laser beam irradiates each sample spot and ion signals from 
hundreds of consecutive shots are averaged across the droplet surface generating a mass 
spectrum. Protein patterns from a discrete number of spots or areas can be compared 
allowing the analysis of molecules within their native environment.
For imaging analyses (MALDI IMS), spectra are recorded for each x,y coordinate into the 
mass range 2.5-30 kDa and finally plotted in 2-dimensions for ion density map construction 
(for each m/z value). Hundreds of protein-specific ion density maps correlated with tissue 
architecture can be generated. Each pixel (spectrum) contains many proteins and 
endogenous peptides that are individually displayed as a function of their position and 
relative intensity within the tissue. Spectra from different regions of interest (i.e papillary, 
reticular and mineralized dermis) can be used for statistical analysis.
In a parallel experiment a histology-directed on-tissue protein digestion approach has been 
applied. Briefly, on-tissue protein digestion was performed using hydrogel discs (1 mm in 
diameter embedded with trypsin solution) placed on the regions of interest of cryosectioned 
samples. After digestion, discs were first manually removed from the tissue surface, then 
properly treated (solvent extracted) and used for LC-MS/MS analysis followed by database 
search for protein identification.
2.4 Tissue preparation, fixation and contaminant removal
We have recently optimized techniques for IMS analysis of human skin and have used only 
minor modifications of our published procedures [15, 16]. Fresh frozen human skin blocks 
(approximately 1cm3) were sectioned at 8 μm using a cryostat (CM 3050 S, Leica 
Microsystems GmbH, Wetzlar, Germany) set at -22 °C.
For MS analysis, serial cryosections were collected, mounted on ITO conductive glass slides 
(Delta Technologies, Stillwater, MN) and allowed to dry at room temperature for 3 min 
prior to matrix deposition. Each conductive slide was rinsed with a Carnoy's (60 mL of 
ethanol, 30 mL of chloroform, and 10 mL of acetic acid) washing protocol [17] in order to 
remove interfering species such as salts and lipids [18,19].
For histological orientation, serial cryosections were mounted on glass microscope slides 
(Fisher Scientific, Pittsburgh, PA) and stained with haematoxylin-eosin and alizarin red, 
respectively. Briefly, for haematoxylin-eosin staining slides were placed in 95% ethanol 
(v/v) 30 sec, purified water 30 sec, haematoxylin 120 sec, water 15 sec, 70% ethanol (v/v) 
15 sec, 95% ethanol (v/v) 15 sec, eosin 60 sec, 95% ethanol (v/v) 15 sec, 100% ethanol (v/v) 
15 sec, xylenes 120 sec. Calcium deposition was evaluated by alizarin red staining. Sections 
were washed at room temperature as follow: xylene (30 sec), 90% ethanol (v/v) (30 sec), 70 
% ethanol (v/v) (30 sec), purified water (30 sec), Alizarin red (100 μL, 30 sec), acetone (15 
sec), acetone/xylene (1:1, v/v, 30 sec) and finally xylene (3×30 sec).
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2.5 MALDI-MS
A crucial step in MALDI MS analyses is represented by the choice of matrix type and of 
matrix deposition mode (e.g., droplet for profiling by MALDI MS and thin homogenous 
matrix layer for imaging MALDI MS). Most of matrices are specific to a mass range or 
family of compounds, moreover, each matrix type has specific ionization property and this 
determines differences in the MS spectrum.
Sinapinic acid, for instance, is the matrix of choice for large proteins, whereas α-cyano-4-
hydroxy-cinnamic acid (CHCA) is the preferred matrix for peptide mapping.
All MS analyses were performed by an AutoflexSpeed MALDI TOF spectrometer (Bruker 
Daltonics, Billerica, MA, USA), equipped with a linear TOF (time-of-flight) analyser, 
operating in positive polarity, accumulating 500 laser shots per position in the case of the 
IMS experiment, and 1000 shots per matrix spot in the case of the profiling experiment, at 
1000 Hz laser frequency over the m/z range of 2,500-30,000 Da. The laser intensity was 
adjusted before each experiment to yield optimal results. Images were acquired at 50 μm 
rastering (spatial resolution). Data acquisition, pre-processing (baseline subtraction of each 
mass spectrum) and data visualization/process verification were performed using the Flex 
software suite (FlexControl 3.0, FlexAnalysis 3.0, FlexImaging 3.0) from Bruker Daltonics. 
Prior to generation of ion density maps, spectra were normalized to the total ion current 
(TIC) in order to minimize spectrum-to-spectrum differences in peak intensity.
2.5.1 Tissue profiling by MALDI MS—A robotic acoustic droplet ejection system was 
used for matrix deposition (Portrait 630 reagent multi-spotter, Labcyte, Sunnyvale, CA) 
[20]. On a 8 μm-cryosection mounted on ITO conductive glass slide, 2 different areas of 
interest, papillary and reticular dermis (calcified and non calcified), were targeted for 
repeated deposition of matrix made of Sinapinic acid (20 mg/mL) in 1:1 acetonitrile/
trifluoroacetic-acid (Sigma Aldrich, St. Louis, MO, USA) at 0.1% (v/v) aq.) that was 
deposited over a series of 6 iterations at 10 droplets (120nL) per iteration. After completion 
of matrix deposition, slides were immediately returned to vacuum desiccation at room 
temperature until MS analysis the same day (figure 2).
2.5.2 Tissue imaging by MALDI IMS—For imaging mass spectrometry, 8 μm-
cryosections mounted on ITO conductive glass slide were coated of a homogenous thin layer 
of matrix using a sublimation device (Chemglass Life Science, Vineland, NJ, USA). 
Sublimation of sinapinic acid (300 mg) was carried out at 145° C, at a pressure of 45 mTorr 
and, after 15 minutes, coating became uniform. The aim of this procedure was to allow the 
mass spectrometer to acquire spectra with a spatial resolution higher than that is possible by 
an array of evenly spaced spots. Finally, tissue sections were quickly rehydrated at 85° C for 
3 min to allow matrix recrystallization.
2.6 Protein identification by LC-MS/MS
Tissue proteins were first digested following an histology-directed in situ digestion method 
using hydrogel discs for trypsin deposition onto the specific tissue regions of interest (e.g.: 
dermis, mineralized dermis) [21]. Digestion was performed at 50°C for 4 hours. Hydrogels 
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(1 mm diameter) were re-hydrated for 15 mins using 20 μL of 1 μg/mL trypsin (in 100 mM 
ammonium bicarbonate) and then placed over the tissue region of interest (skin mineralized 
dermis, adjacent dermis) onto the whole tissue surface guided by the histological features on 
corresponding serial H&E stained tissue section. The tissue sections were incubated in a 
oven at 50 °C for 4 hours to allow protein digestion. Each hydrogel disc was removed from 
the tissue section and placed in separate eppendorf tubes. Peptides imbibed into the 
microwell hydrogels were extracted by organic (50% acetonitrile/5% formic acid) and 
aqueous (100 mM ammonium bicarbonate) solvents, a process that was repeated three times. 
The supernatant collected from each extraction were combined and dried in a centrifugal 
vacuum concentrator (SPD Speedvac, Thermo Scientific, Waltham, MA, USA). The 
reconstituted extracts (20 μL, 0.1% (v/v) formic acid) were stored at -20°C until LC-MS/MS 
analysis was performed.
The reconstituted extracts were analysed by a 70 minutes data dependent LC-MS/MS 
analysis as already described [13]. Thus, MS/MS spectra were searched via SEQUEST 
against a human database (UniprotKB – reference proteome set) that also contained a 
reversed version for each of the entries [22] (figure 2). The criteria used to accept protein 
identification included the extent of sequence coverage, the number of matched peptides 
(almost 3 peptides/protein) and a probabilistic score at p < 0.05 equivalent to 95% 
confidence. All protein identifications underwent false discovery rate (FDR) that measures 
the expected proportion of false positives among the statistically significant findings. The 
FDR cutoff was set at 0% for all proteins in Scaffold (Proteome Software).
2.7 Statistical analysis
Multiple spectra (N=400) per region of interest (papillary dermis, mineralized dermis, 
reticula dermis) were selected from the IMS data. Comparisons of different cutaneous 
regions of interest were conducted using principal component analysis (PCA) to generate 
classification models based on protein profiles patterns. In order to understand how the 
molecular microenvironment within the mineralized dermis itself can influence adjacent 
areas, PCA was performed comparing the mineralized dermis with the adjacent dermis and 
also with the normal dermis from healthy subject. Protein spectra from the MALDI IMS 
sequences were compared. PCA were performed because this is a statistical method 
commonly used to reduce the dimensionality of a multivariate data set to lower dimensions 
while retaining most of the information by displaying and ranking its variance within a data 
set. The PCA transforms the original coordinate system (peaks) into the new coordinate 
system (PC). The new coordinates are called principal components or PCs; so, the first PC 
(PC1) points in the direction of the highest variance, while the second PC (PC2) points in 
the direction of the second highest variance. This statistical tool was used to generate 
classification models based on protein profile patterns. These data were used to confirm the 
existence of two disparate sub-regions within the dermis in pseudoxanthoma elasticum 
disorder affected subjects. The same statistical analysis was carried out for the papillary and 
reticular dermis from a healthy subject. Statistical analyses were carried out using 
ClinProTools software from Bruker (Bruker Daltonics, Billerica, MA, USA).
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2.8 Functional analysis
To discover the Gene Ontology (GO) categories with significantly enriched protein 
numbers, the MS identified proteins were processed by the DAVID (Database for 
Annotation, Visualization and Integrated Discovery) bioinformatics resource v. 6.7, freely 
available at http://david.abcc.ncifcrf.gov. The significance of “protein”-term enrichment was 
assured by a modified Fisher's exact test with a p value <0.01. The protein list was also 
functionally evaluated applying the UniProtKB/Gene Ontology/Biological Process data 
processing (http://www.uniprot.org/).
The list of gene IDs of the differentially expressed spots identified were used to perform 
functional analysis with DAVID 6.7. The list of gene IDs was loaded into the online tool 
(http://david.abcc.ncifcrf.gov/) clicking on Functional annotation clustering and selecting 
gene ID as identifier and gene list as list type. After submission of the list, functional 
classification was performed on the basis of Gene Ontology.
2.9 STRING 9.1 Network Analysis
Possible connections among identified proteins were analyzed by a protein and gene 
network software. For each protein, UniProtKB entry numbers and related gene names were 
acquired in UniProtKB and used for network generation by the use of STRING 9.1 (http://
www.string-db.org/) [23,24]. The UniProtKB entry numbers were inserted into the input 
form as “multiple proteins” and “Homo sapiens” was selected as the reference organism.
3. Results
3.1 Assessment of calcified areas
Morphological analyses of PXE skin confirm the typical accumulation of deformed calcified 
elastic fibres in the middle reticular dermis, as assessed by von Kossa staining on paraffin 
embedded tissue (Fig. 1B) and by ultrastructural observations (Fig. 1C). As clearly shown in 
figure 1C calcified elastic fibres are characterized by enlarged and tortuous shape with 
irregular contour due to the progressive deposition of mineral precipitates starting from the 
elastin core. Only few small normal areas of amorphous elastin are visible at the periphery 
of the fibres.
3.2. MALDI Mass Spectrometry and Imaging Mass Spectrometry
MALDI MS protein profiling shows, within the same PXE specimen, a number of m/z ions 
with differences in peak's relative intensity and distribution depending on the areas 
considered (Fig. 3A).
To further implement these data, IMS analyses (Fig. 3C), integrated with histological 
observations (Fig. 3B), were carried out on control and PXE cryosectioned samples at the 
spatial resolution of 50 μm. Haematoxylin-eosin and alizarin red staining were used to 
visualize tissue morphology and calcified areas, respectively (Fig. 3B). PXE data have been 
technically validated on sections from the contralateral axilla of the same patient (Figs. 3B, 
C). MS and histology data must be combined in order to produce structural and molecular 
information and to create molecular 2D maps. The distribution and the relative expression of 
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hundreds of m/z ions, within morphologically different tissue regions, were displayed. For 
example, calgizzarin (ion at m/z 11651) is mainly distributed close to the epidermis without 
differences between control and PXE specimens. In the case of thymosin beta-4 (TYB-4) 
(m/z 4965), this protein is density mapped in the papillary dermis adjacent to the 
mineralized region in both PXE samples, whereas it is localized within the whole dermis in 
controls, as previously described in normal healthy skin [15]. By contrast, the cleaved form 
of TYB-4 (m/z 4748) is always present in the papillary dermis, whereas it is absent in the 
control reticular dermis and in the mineralized regions. Other ions, as m/z 3183 and 3406, 
appear primarily localized within the mineralized reticular dermis compared to control skin, 
whereas others, as m/z 3429, are similarly distributed in the superficial layer of control and 
PXE skin, or are barely expressed as in the case of m/z 15874 (Fig. 3C). These data indicate 
that a differential protein mapping may characterize PXE samples compared to healthy skin.
In order to highlight similarities and differences among ion patterns, MALDI mass spectra 
recorded from different control and PXE dermal regions were compared by principal 
component statistical analysis (PCA). When the resulting plot is coloured based on the tissue 
region, it appears that control skin molecules from the papillary and the reticular dermis are 
largely intermingled and no sample grouping is clearly evident (Fig. 4A).
By contrast, PCA plots show that, in PXE, proteins from the mineralized skin can be 
grouped in a region clearly separated from those derived either from the papillary (Fig. 4B) 
or the reticular non-mineralized dermis (Fig. 4C). Only a few proteins were clearly 
identified, most being characterized on the basis of their presence within a mass range of 
3-25 kDa.
3.3 Histology-directed identification of proteins from mineralized and non-mineralized 
tissue regions
The term “histology-directed” describes the use of histology combined with MS techniques, 
conducted directly on serial and consecutive tissue sections, for the evaluation of proteome 
changes affecting a specific tissue region. By histology it is possible to investigate the 
morphology of the tissue and to distinguish pathologic from adjacent, presumably healthy, 
areas. For protein identification we have selected tissue regions according to the histology 
and then we have placed hydrogel discs (microwell reactors containing trypsin) within non-
mineralized and mineralized areas of the same PXE specimen.
All identified proteins (acronym, full name and SwissProt accession number) are listed in 
Table 1 and divided according to their presence in mineralized or in non-mineralized regions 
or in both areas. Additional details on mass spectrometry data are provided in 
Supplementary Table S1.
3.4 Gene ontology (GO) classification of identified proteins
Fig. 5A shows that out of 242 proteins, 78 (32%) have been identified in the nonmineralized 
tissue, 147 (61%) in both mineralized and non-mineralized dermis and 17 (7%) in the 
calcified area. Moreover, considering the nonexclusive localization criteria used in GO, 
proteins can appear in several annotation terms within the GO categories (i.e. biological 
process, molecular function and cellular component).
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According to their contribution to one or to more biological processes, identified proteins 
appear mainly involved in cellular processes, cellular component organization and 
biogenesis, multicellular organismal processes and in the response to stimulus (Fig. 5B and 
Supplemental Table S2). As far as their molecular functions, most of the identified proteins 
exhibit binding and structural molecular activity (Fig. 5C and Supplementary Table S3).
Finally, on the basis of their localization, 78 proteins were in the extracellular region and 
166 in organelle structures (Fig. 5D and Supplementary Table S4).
Despite their different distribution and functional properties, the great majority of the 
identified proteins are actually related one to the other, as clearly highlighted by the results 
of the analysis performed using the STRING software. In Fig. 6 the predicted protein-
protein interaction (PPI) networks are shown based on evidence (Fig. 6A) and actions (Fig. 
6B), respectively. In the evidence and in the action PPI, the type of evidence characterizing 
the protein-protein association and the mode of action of proteins are described by lines of 
different colour.
4. Discussion
Ectopic calcification is a pathologic mineralization process of soft connective tissues 
associated to a number of genetic as well as acquired disorders frequently responsible for 
age-related clinical complications [25].
Within this context, Pseudoxanthoma elasticum, due to ABCC6 gene mutations, is 
characterized by progressive calcification affecting, through only partially known 
mechanisms, specific areas of soft connective tissues, as skin, blood vessels and the Bruch's 
membrane in the eye [14]. Abnormal expression of inhibitors of calcification as matrix-Gla-
protein, pyrophosphate, fetuin-A [3,26-28] have been related to the disease, however it is 
still unclear why, within each tissue, there are areas of mineralization together with 
uncalcified regions. It has been suggested that unknown factors within soft connective 
tissues may allow or counteract the deposition of mineral hydroxyapatite crystals at specific 
sites [29].
PXE represents the perfect model to test the relevance of the combined approach of MALDI 
MS (profiling and imaging) together with histology-driven MS protein identification to 
improve the characterization of the diseased tissue and to investigate a large number of 
proteins on a single tissue section. This aspect is crucial in the case of reduced sample 
availability and represents a significant improvement compared to other techniques 
requiring to separately analyse larger amount of tissue by histology, immunohistochemistry 
and/or proteomics. Moreover, this approach avoids the bias of focusing on already known 
molecules or to evaluate proteins without a precise separation between affected 
(mineralized) and unaffected (non-mineralized) areas within the same tissue specimen.
In particular, with respect to tissue architecture and morphology, IMS can produce spatially 
resolved mass spectrometric data that can be combined with histological observations. In 
addition, with a single measurement, IMS allows the direct analysis of molecules/peptides’ 
localisation and of their relative intensity within the tissue. A different protein distribution 
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between PXE and control skin, as well as between different regions within the same 
specimen has been demonstrated, avoiding differences due to individual variability. One of 
the most striking variation between PXE skin samples and control specimens is the peculiar 
localization of TYB-4 in the PXE papillary dermis, whereas protein expression is barely 
detectable in the mineralized reticular dermis. TYB-4 exerts a protective role on ROS-
mediated damages in many cell types, including fibroblasts [30]. The observation that its 
expression is negligible in the calcified dermis may indicate that the mineralized tissue is 
more susceptible to oxidative stress. Consistently, chronic perturbances of redox balance 
have been demonstrated in vivo and in vitro in PXE [31,32], as well as in other conditions 
related to ectopic calcification [33,34]. Moreover, PCA plots clearly show that the 
mineralized dermis is characterized by a peculiar proteomic profile. IMS measures 
molecules by their mass. Although this is sufficient for smaller analytes, such as lipids or 
peptides that can be directly identified on the tissue itself, molecules with molecular weights 
larger then 25 kDa cannot be identified as easily [35].
To tackle this problem, we have therefore enzymatically treated the tissue in order to cleave 
proteins into peptides that can be readily ionized, detected and subsequently identified. In 
particular, we have used a histology directed in situ digestion method using hydrogel discs 
for the enzyme deposition onto the specific tissue region of interest (Fig. 2) [21]. The 
presence/absence of proteins from the analysed samples depends on the enzyme used for the 
digestion and on the technique applied for the extraction. In our work we have used only 
trypsin, without adding any reduction and alkylation agent. Therefore, the number of 
proteins cleaved, as well as the type of proteins identified, is a consequence of this choice. 
Moreover, we have applied very stringent parameters during the process of protein 
identification. This approach may limit the number of listed proteins, although increasing 
the reliability of the identification of detected proteins and therefore a comparative analysis 
was done in the same experimental conditions on different areas of the same sample. 
Trypsin digestion allowed to reveal hundreds of proteins involved in many biological 
processes or belonging to cellular and extracellular components, however, we have preferred 
to list only 242 proteins resulting from the high stringent conditions used in the 
identification process (confidence for analyte identification >95% and FDR set at 0%).
The presence of cellular and metabolic proteins common to all tissue regions indicate that 
cells are spread within the tissue, independently from the presence of calcification, as 
previously demonstrated by morphological observations showing numerous fibroblasts 
closed to mineralized elastic fibres [36]. Interestingly, it has to be underlined that 78 and 17 
proteins appear characteristic of the non-calcified and of the mineralized dermis, 
respectively. Since the enzyme used for digestion and the stringency of the parameters 
applied for databases searching, affect the number of identified proteins, possibly because of 
the experimental conditions used, some proteins already known to be involved in the 
calcification process (i.e. alkaline phosphatase, ectonucleotide pyrophosphatase/
phosphodiesterase 1) were not detected, whereas others were clearly identified.
For instance, carbonic anhydrase (CA2) is specifically associated to the non-mineralized 
region, whereas it is absent from areas of ectopic calcification. Interestingly, CA2 loss of 
function has been actually related to osteopetrosis and to arterial and cerebral calcification 
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[37]. Although the clinical phenotype in PXE is not so severe as that described in patients 
affected by osteopetrosis, never the less it could be suggested that CA2 may be involved in a 
complex network of factors promoting or inhibiting mineral precipitates through changes in 
the local environment [38].
In the calcified dermis we have demonstrated the presence of molecules as ApoE, an 
apolipoprotein that, besides its role in lipid metabolism, is considered a “pathologic 
chaperone” [39] promoting the accumulation of insoluble proteins within the extracellular 
compartment. In agreement with this finding, insoluble aggregates of fibrillar and 
amorphous proteins have been described in association to calcified elastic fibres within the 
PXE dermis [29]. Elastic structures interact with several matrix components, including 
minor collagens [40]. To be noted that in the present study, alpha 1, 2 and 3 chains of 
collagen type VI have been identified in both mineralized and non-mineralized regions, 
whereas a newly discovered alpha 6 chain of collagen type VI, whose biological role is still 
under investigation, appears unexpectedly associated to the calcified dermis. It has been 
proposed that the alpha 6 chain could represent alternatively spliced variants leading to 
abnormal collagen microfibrillar structures possibly related to elastin-associated components 
[41,42]. If these changes represent markers of extracellular matrix alterations, thus favouring 
mineral deposition, it has been never explored and may be worth of additional investigation 
on a larger number of specimens/subjects.
All data are technically reproducible since the same results were obtained from the 
contralateral skin sample and therefore support the rationale to further look at specific 
molecules/pathways. Moreover, as the technology advances, the analysis of fresh frozen 
tissue at higher spatial resolution provides new possibilities to investigate tissue morphology 
at a molecular level using small amount of tissue, a requirement extremely important in the 
case of reduced sample availability.
Finally, the application of MALDI MS (profiling and imaging) as well as of the miniaturized 
hydrogel devices for histology directed on-tissue protein digestion allow us to expand the 
use of these approaches to the clinic, paving the way for the selection of new molecules to 
be validated as pathogenic or as potential pharmacological target.
In conclusion, although validating the pathogenic role of specific molecules was not purpose 
of the present study, these data, for the first time, demonstrate the significance of these 
technical approaches for studying ectopic calcification.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Ectopic calcification is investigated by a new emerging technical approach
• MALDI-MS distinguishes calcified from non calcified areas in the same sample
• Mineralized and non-mineralized areas have a different protein profile
• Proteins never related to the calcification process have been identified
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Fig. 1. 
Clinical phenotype and morphological features observed in PXE. (A-C) Skin laxity (A) is 
associated to the presence of extended areas of calcification in the reticular dermis as shown 
after von Kossa staining (B). By ultrastructural analyses (C) it appears that mineral deposits 
(arrows) are present within elastic fibres, thus altering their typical amorphous structure 
(asterisk).
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Fig. 2. 
Scheme of the approach for the analysis of ectopic calcification associated proteins by 
MALDI MS/IMS and histology-directed on-tissue digestion and protein ID.
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Fig. 3. 
Protein analysis by MALDI MS. (A) Protein profiles were obtained by MALDI MS from 
papillary (blue trace), mineralized (red trace) and non-mineralized reticular dermis (green 
trace) in PXE skin. A close inspection of these profiles revealed that, some signals were 
common to all 3 areas, whereas others were peculiar of a specific region. (B) Optical images 
of tissue sections after haematoxylin-eosin or Alizarin red staining. (C) Seven representative 
density maps were constructed on the basis of IMS data from a 8 μm thick sagittal section of 
control healthy and PXE dermis. Protein signals are depicted as colour images with red 
representing the highest relative intensity for each m/z value.
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Fig. 4. 
Principal component analysis (PCA) of spectra from papillary and reticular dermis. (A) In 
control skin, protein distribution does not show a clear distinction between papillary (blue) 
and reticular (green) dermis. (B-C) In PXE, spectra from the mineralized area (red) are 
distinctly separated from those obtained from the papillary (blue) and the nonmineralized 
reticular (green) dermis.
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Fig. 5. 
GO analysis of proteins identified by histology-directed MS. (A) Venn diagram showing 
that 147 proteins were found in both the mineralized and the non-mineralized areas, while 
17 proteins were uniquely identified within the mineralized dermis and 78 proteins were 
identified only in the region adjacent to the calcified area. By DAVID it is possible to define 
GO biological processes (B), molecular functions (C) and cell components (d) for 242 
identified proteins (See also Table S2-4 supplemental material).
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Fig 6. 
Predicted protein-protein interaction networks (PPI) created by STRING 9.1. (A) Evidence 
PPI in which the line colour represents the types of evidence characterizing the protein-
protein association. (B) Actions PPI in which the different line colour represents the mode of 
protein actions. Each circle indicates an individual protein with the recognized abbreviated 
name.
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Table 1
List of proteins identified by histology-directed MS
Short name Protein name Accession No. Short name Protein name Accession No.
Proteins identified in the mineralized dermis
A2AP Alpha-2-antiplasmin P08697 HEP2 Heparin cofactor 2 P05546
AEBP1 Adipocyte enhancer-binding protein 1 Q8IUX7 MYPR Myelin proteolipid protein P60201
APOE Apolipoprotein E P02649 PCOC1 Procollagen C-endopeptidase enhancer 1 Q15113
C1QC Complement C1q subcomponent subunit C P02747 PEDF Pigment epithelium-derived factor P36955
CAPG Macrophage-capping protein P40121 RL4 60S ribosomal protein L4 P36578
CFAI Complement factor I P05156 SPP24 Secreted phosphoprotein 24 Q13103
CO6A6 Collagen alpha-6(VI) chain A6NMZ7 SRPX Sushi repeat-containing protein SRPX P78539
FILA Filaggrin P20930 THRB Prothrombin P00734
H7C2N1 Prothymosin alpha (Fragment) H7C2N1
Proteins identified in the non-mineralized dermis
AATM Aspartate aminotransferase, mitochondrial P00505 IMMT Mitochondrial inner membrane protein Q16891
ACON Aconitate hydratase, mitochondrial Q99798 K1C18 Keratin 18 P05783
ACOT2 Acyl-coenzyme A thioesterase 2, 
mitochondrial
P49753 K22E epidermal cytokeratin 2 P35908
ACSL1 Long-chain-fatty-acid--CoA ligase 1 P33121 K2C1B keratin 1B Q7Z794
ADH1B Alcohol dehydrogenase 1B P00325 K2C7 keratin 7 P08729
AK1C2 Aldo-keto reductase family 1 member C2 P52895 K2C8 keratin 8, type II cytoskeletal P05787
AL9A1 4-trimethylaminobutyraldehyde dehydrogenase P49189 KAD3 GTP:AMP phosphotransferase, mitochondrial Q9UIJ7
ALDH2 Aldehyde dehydrogenase, mitochondrial P05091 KAP3 cAMP-dependent protein kinase type II-beta 
regulatory subunit
P31323
ANXA3 Annexin A3 P12429 LAMA4 Laminin subunit alpha-4 Q16363
ANXA4 Annexin A4 P09525 LAMB2 Laminin subunit beta-2 P55268
ANXA7 Annexin A7 P20073 LAMC1 Laminin subunit gamma-1 P11047
AOC3 Membrane primary amine oxidase Q16853 LDHB L-lactate dehydrogenase B chain P07195
AT2B4 Plasma membrane calcium-transporting 
ATPase 4
P23634 LIPS Hormone-sensitive lipase Q05469
ATPO ATP synthase subunit O, mitochondrial P48047 MARCS Myristoylated alanine-rich C-kinase substrate P29966
BLVRB Flavin reductase (NADPH) P30043 MDHC Malate dehydrogenase, cytoplasmic P40925
CAH1 Carbonic anhydrase 1 P00915 MYL6 Myosin light polypeptide 6 P60660
CALR Calreticulin P27797 NCALD Neurocalcin-delta P61601
CD44 CD44 antigen P16070 NUCL Nucleolin P19338
DECR 2,4-dienoyl-CoA reductase, mitochondrial Q16698 PEBP1 Phosphatidylethanolamine-binding protein 1 P30086
EF2 Elongation factor 2 P13639 PHB Prohibitin P35232
EFTU Elongation factor Tu, mitochondrial P49411 PIP Prolactin-inducible protein P12273
Short name Protein name Accession No. Short name Protein name Accession No.
ESYT1 Extended synaptotagmin-1 Q9BSJ8 PLIN1 Perilipin-1 O60240
F213A Redox-regulatory protein FAM213A Q9BRX8 PLIN4 Perilipin-4 Q96Q06
FABP4 Fatty acid-binding protein, adipocyte P15090 PRDBP Protein kinase C delta-binding 
protein
Q969G5
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Short name Protein name Accession No. Short name Protein name Accession No.
FAS Fatty acid synthase P49327 PRDX3 Thioredoxin-dependent peroxide 
reductase, mitochondrial
P30048
FBN1 Fibrillin-1 P35555 RAB5C Ras-related protein Rab-5C P51148
FLNB Filamin-B O75369 RAP1B Ras-related protein Rap-1b P61224
G6PI Glucose-6-phosphate isomerase P06744 RBY1B RNA-binding motif protein, Y 
chromosome, family 1 member B
A6NDE4
GNAS2 Guanine nucleotide-binding protein 
G(s) subunit alpha isoforms short
P63092 RL13 60S ribosomal protein L13 P26373
GPDA Glycerol-3-phosphate 
dehydrogenase [NAD(+)], 
cytoplasmic
P21695 S12A2 Solute carrier family 12 member 2 P55011
GRP75 Stress-70 protein, mitochondrial P38646 SDPR Serum deprivation-response protein O95810
HBD Hemoglobin subunit delta P02042 SEPT7 Septin-7 Q16181
HMGB1 High mobility group protein B1 P09429 SPB6 Serpin B6 P35237
HNRH1 Heterogeneous nuclear 
ribonucleoprotein H
P31943 SRBS1 Sorbin and SH3 domain-containing 
protein 1
Q9BX66
HP183 Heterochromatin protein 1-binding 
protein 3
Q5SSJ5 TCP4 Activated RNA polymerase II 
transcriptional coactivator p15
P53999
HYEP Epoxide hydrolase 1 P07099 TENS1 Tensin-1 Q9HBL0
IDHP Isocitrate dehydrogenase [NADP], 
mitochondrial
P48735 TKT Transketolase P29401
IGHG3 Ig gamma-3 chain C region P01860 UBA1 Ubiquitin-like modifier-activating 
enzyme 1
P22314
ILF2 Interleukin enhancer-binding factor 
2
Q12905 XRCC6 X-ray repair cross-complementing 
protein 6
P12956
Proteins identified in mineralized and non-mineralized dermis (common)
1433B 14-3-3 protein beta/alpha P31946 HS90A Heat shock protein HSP 90-alpha P07900
1433E 14-3-3 protein epsilon P62258 HSP71 Heat shock 70 kDa protein 1A/1B P08107
A1AG1 Alpha-1-acid glycoprotein 1 P02763 HSP7C Heat shock cognate 71 kDa protein P11142
A1AT Alpha-1-antitrypsin P01009 HSPB1 Heat shock protein beta-1 P04792
A2BHY4 Complement component C4B A2BHY4 HTTP Haptoglobin P00738
A2MG Alpha-2-macroglobulin P01023 IC1 Plasma protease C1 inhibitor P05155
AACT Alpha-1-antichymotrypsin P01011 IGHA1 Ig alpha-1 chain C region P01876
ACTB Actin, cytoplasmic 1 P60709 IGHG1 Ig gamma-1 chain C region P01857
ACTC Actin, alpha cardiac muscle 1 P68032 IGHG2 Ig gamma-2 chain C region P01859
ACTN1 Alpha-actinin-1 P12814 IQGA1 Ras GTPase-activating-like protein 
IQGAP1
P46940
ACTN4 Alpha-actinin-4 O43707 ITIH1 Inter-alpha-trypsin inhibitor heavy 
chain H1
P19827
AHNK Neuroblast differentiation-associated 
protein AHNAK
Q09666 K1C10 Keratin 10 P13645
ALBU Serum albumin P02768 K1C14 Keratin 14 P02533
ANT3 Antithrombin-III P01008 K1C19 Keratin 19 P08727
ANXA1 Annexin A1 P04083 K1C9 Keratin 9 P35527
ANXA2 Annexin A2 P07355 K2C1 Keratin 1 P04264
ANXA5 Annexin A5 P08758 K2C5 Keratin 5 P13647
Short name Protein name Accession No. Short name Protein name Accession No.
ANXA6 Annexin A6 P08133 K2C6A Keratin 6A P02538
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Short name Protein name Accession No. Short name Protein name Accession No.
APOA1 Apolipoprotein A-I P02647 KCD12 BTB/POZ domain-containing protein 
KCTD12
Q96CX2
ARF3 ADP-ribosylation factor 3 P61204 KPYM Pyruvate kinase isozymes M1/M2 P14618
ARPC4 Actin-related protein 2/3 complex 
subunit 4
P59998 LAC2 Ig lambda-2 chain C regions P0CG05
ASPN Asporin Q9BXN1 LDHA L-lactate dehydrogenase A chain P00338
ATPA ATP synthase subunit alpha, 
mitochondrial
P25705 LMNA Prelamin-A/C P02545
ATPB ATP synthase subunit beta, 
mitochondrial
P06576 LUM Lumican P51884
BGH3 Transforming growth factor-beta-
induced protein ig-h3
Q15582 MDHM Malate dehydrogenase, mitochondrial P40926
CALD1 Caldesmon Q05682 MIME Mimecan P20774
CALM Calmodulin P62158 MOES Moesin P26038
CAP1 Adenylyl cyclase-associated protein 1 Q01518 MYH9 Myosin-9 P35579
CAV1 Caveolin-1 Q03135 MYO1C Unconventional myosin-Ic O00159
CFAH Complement factor H P08603 PDIA1 Protein disulfide-isomerase P07237
CLH1 Clathrin heavy chain 1 Q00610 PDIA3 Protein disulfide-isomerase A3 P30101
CLUS Clusterin P10909 PEPL Periplakin O60437
CO1A1 Collagen alpha-1 (I) chain P02452 PGK1 Phosphoglycerate kinase 1 P00558
CO1A2 Collagen alpha-2(I) chain P08123 PGS1 Biglycan P21810
CO3 Complement C3 P01024 PGS2 Decorin P07585
CO3A1 Collagen alpha-1(III) chain P02461 PLEC Plectin Q15149
CO4A2 Collagen alpha-2(IV) chain P08572 PLSL Plastin-2 P13796
CO4A4 Collagen alpha-4(IV) chain P53420 POSTN Periostin Q15063
CO6A1 Collagen alpha-1(VI) chain P12109 PPIA Peptidyl-prolyl cis-trans isomerase A P62937
CO6A2 Collagen alpha-2(VI) chain P12110 PPIB Peptidyl-prolyl cis-trans isomerase B P23284
CO9 Complement component C9 P02748 PRDX1 Peroxiredoxin-1 Q06830
COEA1 Collagen alpha-1(XIV) chain Q05707 PRDX2 Peroxiredoxin-2 P32119
DPYL2 Dihydropyrimidinase-related protein 2 Q16555 PRELP Prolargin P51888
DPYL3 Dihydropyrimidinase-related protein 3 Q14195 PROF1 Profilin-1 P07737
E9PCV6 Collagen alpha-3(VI) chain E9PCV6 PTMS Parathymosin P20962
ECHA Trifunctional enzyme subunit alpha, 
mitochondrial
P40939 PTRF Polymerase I and transcript release 
factor
Q6NZI2
EF1A1 Elongation factor 1-alpha 1 P68104 Q5TCU3 Tropomyosin 2 (Beta) Q5TCU3
ELN Elastin P15502 Q5VU59 Tropomyosin 3 Q5VU59
ENOA Alpha-enolase P06733 Q6ZN4A Tropomyosin 1 (Alpha), isoform 
CRA_f
Q6ZN40
ENPL Endoplasmin P14625 RAB7A Ras-related protein Rab-7a P51149
F13A Coagulation factor XIII A chain P00488 RLA0 60S acidic ribosomal protein P0 P05388
F5GWP8 Junction plakoglobin F5GWP8 RLA2 60S acidic ribosomal protein P2 P05387
FIBA Fibrinogen alpha chain P02671 ROA2 Heterogeneous nuclear 
ribonucleoproteins A2/B1
P22626
FIBB Fibrinogen beta chain P02675 RS4X 40S ribosomal protein S4, X isoform P62701
Short name Protein name Accession No. Short name Protein name Accession No.
FIBG Fibrinogen gamma chain P02679 RS9 40S ribosomal protein S9 P46781
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Short name Protein name Accession No. Short name Protein name Accession No.
FINC Fibronectin P02751 SERPH Serpin H1 P50454
FLNA Filamin-A P21333 SH3L3 SH3 domain-binding 
glutamic acid-rich-like 
protein 3
Q9H299
G3P Glyceraldehyde-3-phosphate dehydrogenase P04406 SODE Extracellular superoxide 
dismutase [Cu-Zn]
P08294
GDIB Rab GDP dissociation inhibitor beta P50395 SPTB2 Spectrin beta chain, non-
erythrocytic 1
Q01082
GELS Gelsolin P06396 SPTN1 Spectrin alpha chain, non-
erythrocytic 1
Q13813
GLU2B Glucosidase 2 subunit beta P14314 TAGL Transgelin Q01995
GRP78 78 kDa glucose-regulated protein P11021 TBA1B Tubulin alpha-1B chain P68363
GSTP1 Glutathione S-transferase P P09211 TBA4A Tubulin alpha-4A chain P68366
H10 Histone H1.0 P07305 TBB4B Tubulin beta-4B chain P68371
H12 Histone H1.2 P16403 TBB5 Tubulin beta chain P07437
H2A1B Histone H2A type 1-B/E P04908 TENX Tenascin-X P22105
H2B1K Histone H2B type 1-K O60814 TERA Transitional endoplasmic 
reticulum ATPase
P55072
H32 Histone H3.2 Q71DI3 TLN1 Talin-1 Q9Y490
H4 Histone H4 P62805 TPIS Triosephosphate isomerase P60174
HBA Hemoglobin subunit alpha P69905 TRFE Serotransferrin P02787
HBB Hemoglobin subunit beta P68871 VAPA Vesicle-associated 
membrane protein-
associated protein A
Q9P0L0
HEMO Hemopexin P02790 VIME Vimentin P08670
HNRPD Heterogeneous nuclear ribonucleoprotein D0 Q14103 VINC Vinculin P18206
HNRPK Heterogeneous nuclear ribonucleoprotein K P61978
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